{"name":"Biosyn","slug":"biosyn","ticker":"","exchange":"","domain":"","description":"Jurassic Park, later referred to as Jurassic World, is an American science fiction media franchise created by Michael Crichton, centered on a disastrous attempt to create a theme park of cloned dinosaurs. It began in 1990 when Universal Pictures and Amblin Entertainment bought the rights to Crichton's novel Jurassic Park before it was published. The book was successful, as was Steven Spielberg's 1993 film adaptation. The film received a theatrical 3D re-release in 2013, and was selected in 2018 for preservation in the United States National Film Registry by the Library of Congress as being \"culturally, historically, or aesthetically significant\". Crichton's 1995 sequel novel, The Lost World, was followed by a 1997 film adaptation, also directed by Spielberg. Crichton did not write any further sequels in the series, although Spielberg would return as executive producer for each subsequent film, starting with Jurassic Park III (2001).","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":1291529,"revenueGrowth":6.4,"grossMargin":0,"rdSpend":157919,"netIncome":15795,"cash":1891514,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2019"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Second dose","genericName":"Second dose","slug":"second-dose","indication":"Other","status":"marketed"}]}],"pipeline":[{"name":"Second dose","genericName":"Second dose","slug":"second-dose","phase":"marketed","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxPVW8wQ1RudUpiSE1saG5hYXBUdjFGcmgybUh0VnY0bU5SYmVjaTFtbDd6Ym5zd1k4NWpkdVpuR293V3Zxa2oyTUNXZ2QwS2E5a1RtVFFOZExWM2xxd2VwWnZ5VmY4QV9KY2VRZW1XTHl0Z1RYY1BGeDhIU0JMY2s1VGw4bGQ3TXdQanJLN3FUM1BsNUxrWGJPd3pWUndpVTVUV2poU2k5cEFaYTAtWnpDQzVIdWpBbGRDQlhmN0VQN0hYWEFYV1BvT3BvejNWcGdz?oc=5","date":"2026-04-08","type":"regulatory","source":"TipRanks","summary":"Gujarat Themis Biosyn Publishes SEBI-Mandated Notice on Physical Share Demat Window - TipRanks","headline":"Gujarat Themis Biosyn Publishes SEBI-Mandated Notice on Physical Share Demat Window","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-10","type":"pipeline","source":"simplywall.st","summary":"Unpleasant Surprises Could Be In Store For Gujarat Themis Biosyn Limited's (NSE:GUJTHEM) Shares - simplywall.st","headline":"Unpleasant Surprises Could Be In Store For Gujarat Themis Biosyn Limited's (NSE:GUJTHEM) Shares","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxOLUlxc1ZVUHRIaUc4cUhIZERPOXlTa1R5TlVnSm92T05TYTUxeEUxRVh2MmdkTzYtU2t0NFYyd1J0N05wWGtJQzgxVEFzSWRxU1ZWbnBSR2sxVUtGS0hiQS04dktrcUQzNGRyVmNIdlRRRUlXeElNNWVVdVEtTGx1RmdPLVhXQUwyQ3ljOXlYMi1JQkJtRThySlJlNEFVSWVCY1JPbkxzZks4ZXhweEFEVWZ3TGpRaFhUaWRfX0JSMkV4VDJQUGk2M0FlQVk?oc=5","date":"2025-11-13","type":"earnings","source":"scanx.trade","summary":"Themis Medicare Reports Loss in Q2 FY2026, Withdraws Merger with Gujarat Themis Biosyn - scanx.trade","headline":"Themis Medicare Reports Loss in Q2 FY2026, Withdraws Merger with Gujarat Themis Biosyn","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi2wFBVV95cUxOT2FOa3hxMHVuUnZSdVhNdDFIYmc0VURlNTNobEd3elVJMDV3Ul93d3JZWEk3LW1Xek9CWDVOVm5rNm5CUkw1cHBKY1c0SEJ1eXJGdzFVUFlIanl0Z2Y4VExuME5OWDVPelFNaWN6ZUJQTFMtajBobGpzNkhyWFRlMEpKZHVOQW1iTXp6d0pqR0ZVWGpwTGx3TmZENnhvYXRfQ0I5TjI1YWIwX2ptRzE2Vjh2NDVnWDZnMDNfRUZKXzFqdzZYVUZYSzFOalZGdUZvS2I5ek9oMHpSNm_SAeIBQVVfeXFMT0ozODE4ZTJNQlIxQlBSZDgwVWJPZGx4QWdFUlA2SS1yNFlQVzJIenRwX0pSVkpETTdPRDRuWjJZTGN0LTFmcjcwRjdXTXczSXRqak95WExDOXlHeEY0ZHAzVm1lQzhCOURDOW5NUS1LQW4zMjhldUFXWnJYOGFYQkJIUUJkX1BoYTlPN1c2U3ViV2tuU253MkEtSjd4UkYyd3o5RkFmQVM1X1MtM1pseS1semxua09BMlRUaHN4UzhGUnd3VV9RRW5nMUs4azVScDVONFoxVUtNQmJ4bHdUZl9HZw?oc=5","date":"2025-11-02","type":"pipeline","source":"financialexpress.com","summary":"Are these 3 pharma companies the market’s best-kept secret? Their numbers say yes. - financialexpress.com","headline":"Are these 3 pharma companies the market’s best-kept secret? Their numbers say yes.","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-19","type":"pipeline","source":"Indian Pharma Post","summary":"Gujarat Themis Biosyn doubles fermentation production capacity at Vapi - Indian Pharma Post","headline":"Gujarat Themis Biosyn doubles fermentation production capacity at Vapi","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMickFVX3lxTE9JZ052dVJwcUtldUlaakRTR0dPNTkxYTk1RWZ4M2pJbFpucVdxSVptWG03T3FYbG1RVGVKd3FRVDhJSjRwUndqTC1Mc3BYZHRBVnpHSDJ3V0t4QnVCTC1xZFVLeE5lNlczTFBlV19wQmJBdw?oc=5","date":"2025-07-26","type":"pipeline","source":"Insightace Analytic","summary":"Heparinoid Market Exclusive Research Report 2025 - Insightace Analytic","headline":"Heparinoid Market Exclusive Research Report 2025","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-06-16","type":"pipeline","source":"Moneycontrol.com","summary":"Stocks to Watch Today: ITC, Bajaj Finance, Sun Pharmaceutical, Syngene, Natco Pharma, Vedanta, Sacheerome... - Moneycontrol.com","headline":"Stocks to Watch Today: ITC, Bajaj Finance, Sun Pharmaceutical, Syngene, Natco Pharma, Vedanta, Sacheerome...","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-05-28","type":"earnings","source":"simplywall.st","summary":"Gujarat Themis Biosyn's (NSE:GUJTHEM) Sluggish Earnings Might Be Just The Beginning Of Its Problems - simplywall.st","headline":"Gujarat Themis Biosyn's (NSE:GUJTHEM) Sluggish Earnings Might Be Just The Beginning Of Its Problems","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTFBtdllPbFJ6LXdkb09vZ2VaNXZhQWswcUJDcHRHRDcwel9xY081cGtoa0JIV29lb3NUb1FwcF9hcHdkMUlxUG1rMWFXX0ZBZUxyamtWTHdDdlVjdUUw?oc=5","date":"2025-02-25","type":"pipeline","source":"TradingView","summary":"GUJTHEM Stock Price and Chart — NSE:GUJTHEM - TradingView","headline":"GUJTHEM Stock Price and Chart — NSE:GUJTHEM","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxQX3ZDb0pPclRtMURhOThRQ2JqV1VlbFFZY1lpaTJfX0VpQkpRTGNsYW43ZWlDRFV5SmpGdm4yUUliREUtdnp2SnNaajNrTUhtMzhxZkpFd1BpYU50R2lhV09OV0xvRGcxYUxHTEFwZEdsaW5od3g2TU5uTEJTcm15Q3JJVEE?oc=5","date":"2024-02-02","type":"pipeline","source":"Pharmaceutical Technology","summary":"Biosyngen’s liver cancer therapy receives fast track designation - Pharmaceutical Technology","headline":"Biosyngen’s liver cancer therapy receives fast track designation","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE44MDE3cEp6NVc2S29LY0dtdUFwVVNQQWFWVS1sUlVIVlY0TXV0X0xPSU9LeHZTLWJSYWk5eVFBazRacmROdEJQNTRsMHVCc3h5UTRlaEVRZkljS1RJZjRSZVdzT0R4M3cxSXVlMjZR?oc=5","date":"2023-09-01","type":"pipeline","source":"koreabiomed.com","summary":"Huons extends contract to exclusively distribute Biosyn's selenium deficiency treatment in Korea - koreabiomed.com","headline":"Huons extends contract to exclusively distribute Biosyn's selenium deficiency treatment in Korea","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQY3FESm5TeGZvR2kxYXlSbTc0NkJ0RG05Nm9NWlMtRVZoal8zYUlYSVdDd3dYVmVQWVk5MkRDd1c5dkw3MVg4UUVFaDZrcmxBQVBlSWNUQkFYclZGTWFFM3JKc1FieGJZQ0M0VU00dUlSYkVQVms0MmVEUFBzRHlhNmJscnJva0tzV3RjS004T3Job00?oc=5","date":"2022-06-10","type":"pipeline","source":"Vanyaland","summary":"‘Jurassic World: Dominion’ Review: The wonder’s gone extinct - Vanyaland","headline":"‘Jurassic World: Dominion’ Review: The wonder’s gone extinct","sentiment":"neutral"},{"date":"2022-03-23","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: FORM 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2022-01-21","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"},{"date":"2022-01-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: FORM 8-K","headline":"SEC 8-K: FORM 8-K","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":1291529,"revenuePeriod":"2019-04-30","revenueHistory":[{"value":1291529,"period":"2019-04-30"},{"value":1214213,"period":"2018-04-30"},{"value":1292569,"period":"2017-04-30"},{"value":1337952,"period":"2016-04-30"},{"value":1337952,"period":"2016-04-30"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":157919,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":15795,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":1891514,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}